期刊文献+

帕金森病的神经保护治疗 被引量:3

The neuroprotection of Parkinson's disease
原文传递
导出
摘要 帕金森病是一种常见的中枢神经系统变性疾病,其神经退变进行性加重,会导致患者严重残疾,寿命缩短,目前尚无有效的预防和根治措施。大量研究表明,帕金森病的发病机制涉及到线粒体功能和氧化应激,免疫反应,营养因子缺乏,细胞凋亡,蛋白质异常表达等。神经保护治疗能够延缓或终止帕金森病的进展,预防残疾的进一步加重。 Parkinson' s disease is a common neurodegenerative disorder. In Parkinson' s disease, neu- rodegeneration is progressive and leads to severe disability and life expectancy. There is no effective preventative or curative therapies at present. Substantial evidence supports the involvement of mitochondrial dysfunction and oxidative stress, inflammation,lack of trophic factors, apoptosis, and changed protein handling in the pathogenesis of Parkinson' s disease, Neuroprotective therapy can slow or stop the disease progression and prevent the development of cumulative disability. We will troduce several promising targets and neuroprotective therapies for the neurodegeneration of Parkinson' s disease.
出处 《国际免疫学杂志》 CAS 2015年第4期383-387,共5页 International Journal of Immunology
基金 黑龙江省留学归国科学基金项目(LC201040)
关键词 帕金森病 神经保护 免疫调节 凋亡 Parkinson's disease Neuroprotection Immunomodulation Apoptosis
  • 相关文献

参考文献29

  • 1Schapira AH, Olanow CW, Greenamyre JT, et al. Slowing of neuro- degeneration in Parkinson' s disease and Huntington' s disease: future therapeutic erspectives [ J ]. Lancet, 2014,384 ( 9942 ) : 545-555.
  • 2Shin YC, Sheng TI'. The epidemiology of Parkinson' s disease [J]. TzuChiMed ,2010,22(2): 73-81.
  • 3Schapira AH, Olanow CW. Neuroproteetion in Parkinson disease: mysteries, myths, and misconceptions [ J ]. JAMA ,2004 ,291 ( 3 ) : 358-364.
  • 4汪锡金,张煜,陈生弟.帕金森病发病机制与治疗研究十年进展[J].中国现代神经疾病杂志,2010,10(1):36-42. 被引量:89
  • 5Schapira AH, Tolosa E. Molecular and clinical prodrome of Par- kinson disease: implications for treatment [J]. Nat Rev Neural, 2010,6(6) : 309-317.
  • 6Blander G, Guarente L. The Sir2 family of protein deacetylases [J]. Annu Rev Biochem 2004,73 : 417-435.
  • 7Khan MM, Ahmad A, Ishrat T, et al. Resveratrol attenuates 6- hydroxydopamine-induced oxidative damage and dopamine deple- tion in rat model of Parkinson' s disease [J]. Brain Res,2010, 1328 : 139-151.
  • 8Wang X,Winter D,Ashra G,et al. PINKl and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility [J]. Cell,2011,147(4) : 893-906.
  • 9Patel NK,GilISS GDNF delivery for Parkinson~ disease [J]. Acta Neutorhir Supp1,2007,97 ( Pt 2 ) : 135-154.
  • 10Hunot S,Hirsch EC. Neuroinflammatory processes in Parkinson~ disease [J]. Ann Neuro,2003,53(3) : $49-58.

二级参考文献59

  • 1何卿玮,王加才,彭国光,王法祥.pVAX1-IL-4/SYN-B融合质粒的构建及表达[J].免疫学杂志,2009,25(5):588-590. 被引量:8
  • 2Drouot X, Oshino S, Jarraya B, et al. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron, 2004, 44:769-778.
  • 3Benvenuti E, Cecchi F, Colombini A, et al. Extradural motor cortex stimulation as a method to treat advanced Parkinson's disease: new perspectives in geriatric medicine. Aging Clin Exp Res, 2006, 18:347-348.
  • 4Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA, 2002, 99:2344-2349.
  • 5Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128(Pt 12):2977-2986.
  • 6Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA, 2008, 105:5856-5861.
  • 7Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase Ⅰ trial. Lancet, 2007, 369:2097-2105.
  • 8Volz TJ, Farnsworth SJ, Rowley SD, et al. Age- dependent differences in dopamine transporter and vesicular monoautine transporter 2 function and their implications for methamphetamine neurotoxicity. Synapse, 2009, 63:147-151.
  • 9Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol, 2006, 147 Suppl 1:287-296.
  • 10Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol, 2009, (193):589- 615.

共引文献90

同被引文献34

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部